Effects of Simultaneous Transurethral Resection of Non-Muscle-Invasive Bladder Cancer and Benign Prostatic Hyperplasia

Abstract

Purpose: To evaluate the effects of simultaneous transurethral resection of bladder tumor (TURB) and transurethral resection of prostate (TURP) in patients with non-muscle-invasive bladder cancer and benign prostatic hyperplasia (BPH). Materials and Methods: From March 1995 to February 2007, TURB was performed for transitional cell carcinoma (TCC) of the bladder in 395 men by a single surgeon. Among these patients, 24 patients underwent TURB and TURP simultaneously for BPH as well as non-muscle-invasive TCC without bladder neck or prostatic urethral invasion and were followed up for at least 12 months (group 1). For purposes of comparison, the data from 165 men who underwent TURB alone for non-muscle-invasive TCC of the bladder (group 2) were also reviewed. Results: There were no significant differences in the clinicopathological variables of bladder cancer between the 2 groups. The 60-month overall recurrence-free, recurrence-free at bladder neck or prostatic urethra, and progression-free probability were 68.4%, 80.0%, and 89.4% in group 1 and 72.5%, 91.9%, and 94.5% in group 2, respectively. Kaplan-Meier curves showed that there were no significant differences in the overall recurrence- free rate (p=0.688), recurrence-free rate at bladder neck or prostatic urethra (p=0.867), or progression-free rate (p=0.885) between the 2 groups. Among the clinicopathological variables, no predictor of recurrence was identified in group 1. Conclusions: Simultaneous TURP during TURB does not increase the recurrence or progression rates of bladder cancer. TURP can be safely performed during TURB in patients with non-muscle-invasive bladder cancer and BPH.